NATALIZUMAB

Information current as at: 1 October 2025

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Tyruko®
Pharmaceutical company:
SANDOZ PTY LTD
Condition/indication:
(therapeutic use)
  • Relapsing-remitting multiple sclerosis (RRMS)
PBAC Submission type:
New PBS listing (Category 3)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
March 2025 PBAC meeting
Opportunity for consumer comment:
Open 27/11/2024 and close 29/01/2025 (see PBS Website)
PBAC meeting:
Held on 12/03/2025
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
23/09/2025
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred

Case ID: a999

Page last updated: 30 September 2025

v.9.18